<?xml version='1.0' encoding='utf-8'?>
<document id="16100293"><sentence text="The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction." /><sentence text="Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile"><entity charOffset="114-124" id="DDI-PubMed.16100293.s2.e0" text="sildenafil" /><entity charOffset="126-136" id="DDI-PubMed.16100293.s2.e1" text="vardenafil" /><entity charOffset="142-151" id="DDI-PubMed.16100293.s2.e2" text="tadalafil" /><pair ddi="false" e1="DDI-PubMed.16100293.s2.e0" e2="DDI-PubMed.16100293.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16100293.s2.e0" e2="DDI-PubMed.16100293.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16100293.s2.e0" e2="DDI-PubMed.16100293.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16100293.s2.e1" e2="DDI-PubMed.16100293.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16100293.s2.e1" e2="DDI-PubMed.16100293.s2.e2" /></sentence><sentence text=" This review comparatively discusses the major characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, including bioavailability and rate of absorption, Biopharmaceutical Classification System categorization, elimination mechanisms, and metabolic profile including active metabolites, as well as the drug-drug interaction potential and modification of pharmacokinetic properties under selected physiologic and pathophysiologic conditions" /><sentence text=" The review is aimed at providing comparative clinical pharmacology data to allow for scientifically rational, evidence-based prescribing and dosing decisions regarding the clinical use of these medications for the treatment of erectile dysfunction" /><sentence text="" /></document>